Abstract
Zygomycosis is an invasive infection that can occur particularly
in patients with haematological malignancy. The
causative fungi are members of the order Mucorales, and
individual species within this group require a high level of
laboratory skill to be identified. Zygomycosis can present as
rhinocerebral, pulmonary, or disseminated disease, with a
rapid clinical course. The optimal management of these cases
requires early diagnosis, aggressive antifungal therapy and,
when possible, surgical debridement. Founded on clinical
experience, but without the benefit of comparative studies,
liposomal amphotericin B has become the therapeutic agent
of choice. Posaconazole is an orally administered triazole with
a demonstrated in vitro and in vivo activity against most
Zygomycetes that is comparable to that of amphotericin B.
Studies on salvage therapy with posaconazole have yielded
promising results, and successful case reports are also
available. As an adjuvant approach, iron chelation with
deferasirox has shown promising results, although clinical
experience is still limited.
Lingua originale | English |
---|---|
pagine (da-a) | 597-606 |
Numero di pagine | 10 |
Rivista | British Journal of Haematology |
Volume | 146 |
Stato di pubblicazione | Pubblicato - 2009 |
Keywords
- leucemia
- zigomicosi